ReoPro rules: results from the ‘Do Tirofiban and ReoPro Give Similar Efficacy Trial’ (TARGET)

Author： Doggrell Sheila A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.9, 2001-09, pp. : 1507-1509

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase III trial of Reopro [abciximab] for the treatment of patients with acute ischaemic stroke (AbESTT-II) has been temporarily suspended

By  

Reactions Weekly, Vol. 1, Iss. 1073, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Abciximab (Reopro): a clinically effective glycoprotein IIb/IIIa receptor blocker

By de Belder M.   Sutton A.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 10, 1998-10 ,pp. : 1701-1717

Informa Healthcare

Access to resources Recommend Favorite

(Pro)renin Receptor as a New Drug Target

By  

Current Pharmaceutical Design, Vol. 17, Iss. 33, 2011-11 ,pp. : 3611-3621

Bentham Science Publishers

Access to resources Recommend Favorite

Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 9, 2012-07 ,pp. : 1742-1749

Bentham Science Publishers

Access to resources Recommend Favorite

Pro and Antiinflammatory Properties of Toxins from Animal Venoms

By  

Current Drug Targets. Inflammation & Allergy, Vol. 4, Iss. 3, 2005-06 ,pp. : 401-411

Bentham Science Publishers

Access to resources Recommend Favorite